EIF2AK3 and melanoma: Targeting PD-1 and CXCR4 on PES43 melanoma cells reduced cell growth and inhibited survival signaling (pERK/pAkt) [15–17] strengthen the effect of nivolumab that impaired pERK/pAkt and p4EBP1.